Abbott Laboratories provided earnings guidance for the full-year 2023. For the year, the company expects diluted earnings per share from continuing operations under GAAP of $3.05 to $3.25. Abbott projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, of high-single digits and COVID-19 testing-related sales of around $2.0 billion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
104.7 USD | +1.91% |
|
+1.58% | -4.90% |
07-15 | Equity Markets Higher After Fed Chair Powell's Comments | MT |
07-15 | Equity Markets Rise Intraday After Fed Chair Powell's Comments | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.90% | 179B | |
-1.36% | 100B | |
-7.64% | 46.16B | |
+18.16% | 44.81B | |
+9.63% | 44.38B | |
+13.63% | 29.53B | |
+22.31% | 25.83B | |
-7.12% | 23.97B | |
+4.03% | 22.5B | |
-8.75% | 22.11B |
- Stock Market
- Equities
- ABT Stock
- News Abbott Laboratories
- Abbott Laboratories Provides Earnings Guidance for the Full-Year 2023